Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 8/20 | 0.44 |
| ▸ | RARG | P13631 | 8/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 4/20 | 0.41 |
| ▸ | RXRB | P28702 | 4/20 | 0.41 |
| ▸ | RARA | P10276 | 6/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.40 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17444524 | 0.87 | KDM1A (0.43) | RARBRARGKDM4EALDH1A1KDM1A | |
| SCHEMBL19042908 | 0.86 | RARB (0.41) | RARBRARGKDM4EMAPTALDH1A1 | |
| SCHEMBL17436019 | 0.81 | ALDH1A1 (0.47) | KDM4EMAPTALDH1A1TDP1MEN1 | |
| SCHEMBL17444520 | 0.81 | OTUD7B (0.45) | HTT | |
| SCHEMBL29930072 | 0.80 | KDM4E (0.44) | RARBRARGKDM4EMAPTALDH1A1 | |
| SCHEMBL31390939 | 0.80 | MAPK14 (0.43) | RARBRARGALDH1A1KDM1A | |
| SCHEMBL22058140 | 0.78 | KDM1A (0.40) | RARBRARGKDM1A | |
| SCHEMBL7400148 | 0.78 | KDM4E (0.54) | RARBRARGKDM4EMAPTALDH1A1 | |
| Bromide SCHEMBL20954964 | 0.77 | KDM1A (0.39) | RARBRARGKDM1A | |
| SCHEMBL30468541 | 0.77 | TSHR (0.40) | RARBRARGKDM4EALDH1A1KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189854-B2 | Substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2019-01-29 | — | — | US | disclosed |
| EP-3169681-A1 | NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2017-05-24 | — | — | EP | disclosed |
| US-20170066776-A1 | Novel substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2017-03-09 | — | — | US | disclosed |
| US-9540349-B2 | Substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2017-01-10 | — | — | US | disclosed |
| US-20160016937-A1 | Novel substituted pyrimidine compounds | GRUENENTHAL GMBH (DE) | 2016-01-21 | — | — | US | disclosed |
| WO-2016008593-A1 | NOVEL SUBSTITUTED PYRIMIDINE COMPOUNDS | Grünenthal GmbH (DE) | 2016-01-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189854-B2 | Substituted pyrimidine compounds | TYMP, PDE4A, DPYD | RARB 1341/4885RARG 2071/4885KDM4E 1378/4885 |
| US-20160016937-A1 | Novel substituted pyrimidine compounds | PDE4A, PDE4B, TYMP | RARB 1169/4885RARG 1814/4885KDM4E 1354/4885 |
| US-20170066776-A1 | Novel substituted pyrimidine compounds | PDE4A, PDE4B, TYMP | RARB 1169/4885RARG 1814/4885KDM4E 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.